Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Inhibitors of T-cell activation
US9834604B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9834604-B2 |
| Application number | US-201214128461-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2012 |
| Priority date | Jun 30, 2011 |
| Publication date | Dec 5, 2017 |
| Grant date | Dec 5, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
First claim
Opening claim text (preview).
The invention claimed is: 1. A bispecific fusion protein comprising a ligand specific for CTLA-4 selected from the group consisting of CD80 (B7-1) and CD86 (B7-2), and a ligand specific for a peptide-MHC class II (pMHCII) complex, wherein the CD80 or the CD86 and the ligand specific for the pMHCII complex are spaced apart by a linker. 2. The bispecific fusion protein according to claim 1 , wherein the ligand specific for the pMHCII complex is LAG-3. 3. The bispecific fusion protein according to claim 1 , wherein the linker is one or more of a polyamino acid sequence and an antibody Fc domain. 4. The bispecific fusion protein according to claim 3 , wherein the polyamino acid sequence is G9 (Gly-9). 5. The bispecific fusion protein according to claim 1 , wherein the ligand specific for CTLA-4 is CD80. 6. The bispecific fusion protein according to claim 5 , wherein the CD80 is mutated to increase specificity for CTLA-4 over CD28. 7. The bispecific fusion protein according to claim 6 , wherein CD80 is human CD80 comprising the amino acid sequence SEQ ID NO:15 modified to include at least one of mutations W84A, K71G, K71V, S109G, R123S, R123D, G124L, S190A, S201A, R63A, M81A, N97A and E196A. 8. The bispecific fusion protein according to claim 7 , wherein CD80 comprises the mutation W84A or E196A of human CD80. 9. The bispecific fusion protein according to claim 2 , wherein LAG-3 is mutated to increase specificity for pMHCII. 10. The bispecific fusion protein according to claim 9 , wherein LAG-3 is human LAG-3 comprising at least one of mutations R73E, R75A, R75E and R76E. 11. The bispecific fusion protein according to claim 10 , wherein LAG-3 comprises the mutation R75A or R75E. 12. The bispecific fusion protein according to claim 1 , wherein the ligand specific for the pMHCII complex is an anti-MHCII antibody. 13. The bispecific fusion protein according to claim 1 , wherein the ligand specific for CTLA-4 is CD86.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9834604B2 cover?
- The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
- Who is the assignee on this patent?
- Zhu Yunxiang, Karman Jozsef, Wei Ronnie, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).